$3.55
-0.45-11.25%
Last update: Nov 12, 11:25 AM
Corbus Pharmaceuticals Holdings Inc
CRBPNASDAQ
Corbus Pharmaceuticals fell 64.3% from $11.19 to $4.00, behind the S&P 500's +11.2%. Its worst day was May 26 (−30.3%), and its low came Nov 5 at $2.86.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.90 missed the $-1.74 estimate on $0.00 revenue.
0.0% · S&P 500 +0.1%
EPS of $-1.25 beat the $-1.66 estimate on $0.00 revenue (est. $1.1M).
Story events cover the past 12 months · Times ET
+19.2%, the year's best day · S&P 500 +0.9%
EPS of $-1.23 beat the $-1.23 estimate on $0.00 revenue.
+3.5% · S&P 500 −0.2%
Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forwardConfirmed ORR of 42.9% observed in 2L
−30.3%, the year's worst day · S&P 500 +0.7%
EPS of $-1.81 missed the $-1.25 estimate on $0.00 revenue.
+1.8% · S&P 500 −0.2%
Corbus Pharmaceuticals shares fell 16.4%, while the S&P 500 fell 0.5%.
−16.4% · S&P 500 −0.5%
EPS of $-1.81 missed the $-1.31 estimate on $0.00 revenue (est. $1.1M).
+11.6% · S&P 500 −0.4%
Where it ended: a close of $4.00 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-1.35).
Nothing in the past 12 months.
All CRBP dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRBP and SPY from Benzinga historical bars. Not investment advice.
